http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1608339-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c90310252cb8283cf96f3dc8eb0fe008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59c6a921f33fe0adc58c2b6177184515 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bcff13f8573db698307f919e6385d5c4 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-455 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C233-00 |
| filingDate | 2003-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74031402327f6c4bad3bfa71780fccb6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_753969f47a575efa98aa87c6a555fb13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9260fc09d07f651b87eeff2ae9fd0195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7372f5a998a53f0c1da3f5bc13a3dbc7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7cd9cb7c38e568f6e532c878b9930499 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_211f725d4e1d8f3836571cbfdaa15347 |
| publicationDate | 2005-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1608339-A1 |
| titleOfInvention | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| abstract | A pharmaceutical composition comprising a co-crystal of an API and a co-crystal forming compound; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, oheterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal forming compound has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal forming compound are capable of co-crystallizing from a solution phase under crystallization conditions. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105997919-A |
| priorityDate | 2003-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1147.